Background: Antithrombotic treatment with heparin together with antiplatelet agents reduces the incidence of ischemia in patients with coronary artery disease. associated with fewer adverse reactions.

Aim: To evaluate and compare the clinical and obtained results of the use of enoxaparin and standard unfractionated heparin in patients with coronary heart disease.

Methods: This is a non-invasive planned surveillance demonstration conducted at a tertiary hospital in Pakistan. Adult male and female patients with coronary artery infection (CAD) between the ages of 30 and 70 were recently analyzed or included patients with a history of heart cancer. The intermediate layer is injected with enoxaparin for 5 days. Resting the ECG position, prothrombin time, and ADRs were measured individually in all patients from 1 to 21 days.

Result: Compared to the patient's unfractionated heparin, normal prothrombin times were generally higher (P and <0.002), while total hypokalemia was lower. (P and <0.04) in the patient's enoxaparin stratification. Angina pectoris and side effects such as death, morbidity, encephalopathy and sudden onset were less common in the patient's enoxaparin fraction than in the unfractionated heparin fraction, and the contrast was negligible

Conclusions: Antithrombotic therapy with enoxaparin and aspirin is safer and more convincing than unfractionated heparin and headache drugs because it reduces the incidence of ischemic events in patients with unstable or tissue angina. The myocardium dies in the early stages.

Keywords: Anticoagulant, coronary heart disease, enoxaparin, safety, and efficacy, unfractionated heparin